热门资讯> 正文
Biogen介绍了Salanersen 1b期研究的其他结果
2026-03-11 20:04
- New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy
- Salanersen is a novel antisense oligonucleotide and has the potential to deliver high efficacy in SMA with once-yearly dosing
- Biogen also debuted the design of the Phase 3 salanersen clinical trial program which is being initiated at sites around the world
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
